Latency-Associated Nuclear Antigen 2 (LANA2) anticorps

N° du produit ABIN363228

Cet anticorps anti-Latency-Associated Nuclear Antigen 2 (LANA2) Monoclonal Souris (Clone CM-A807) (ABIN363228) détecte spécifiquement Latency-Associated Nuclear Antigen 2 (LANA2) dans IF, IP, IHC, ELISA et WB. L’anticorps est réactif avec des échantillons de Kaposi's sarcoma-associated herpesvirus (KSHV).

Aperçu rapide pour Latency-Associated Nuclear Antigen 2 (LANA2) anticorps (ABIN363228)

Antigène: Latency-Associated Nuclear Antigen 2 (LANA2)

Reactivité: Kaposi's sarcoma-associated herpesvirus (KSHV)

Hôte: Souris

Clonalité: Monoclonal

Application: Immunofluorescence (IF), Immunoprecipitation (IP), Immunohistochemistry (IHC), ELISA, Western Blotting (WB)

Clone: CM-A807

Détail du produit

Specificité: Reacts with human and murin Kaposi's sarcoma-associated herpes virus (KSHV) ~66-70 kDa LANA2 protein and shows no cross-reactivity to cellular proteins

Purification: Purified (protein G)

Immunogène: Recombinant LANA2 fusion protein

Isotype: IgG1 kappa

Information d'application

Indications d'application:

Working dilution: Optimal dilution should be determined by the end user.
The following are guidelines only :
- IHC : 1/10 to1/2000 - IF : 2 to 4 μg/mL - IP : 2 to 4 μg/mL - WB : 2 to 4 μg/mL

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 2 mg/mL

Stock: 4 °C/-20 °C

Stockage commentaire: Short term storage at +4°C. For extended periods store in aliquots at -20°C. Antibodies are guaranteed for 6 month from date of receipt.

Date de péremption: 6 months

Détail du antigène

Antigène: Latency-Associated Nuclear Antigen 2 (LANA2)

Classe de substances: Viral Protein

Sujet: LANA2 (latency-associated nuclear antigen) is an inhibitor of p53-induced transcription in reporter assays and may be an apoptosis antagonist.It is a nuclear protein associated with Kaposi's sarcoma-associated herpes virus (KSHV), or human herpes virus 8.It is found in abundance in the nuclei of cultured cells from KSHV-infected hematopoietic tissues, such as PEL (primary effusion lymphoma) and CD (multicentric Castleman's disease).It does not appear to be expressed in KS (Kaposi's sarcoma) lesions.